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ABSTRACT
Introduction: Hyperkalemia risk is increased in
diabetes, particularly in patients with renal
impairment or those receiving
angiotensin-converting enzyme (ACE)
inhibitors, angiotensin receptor blockers
(ARBs) or potassium-sparing diuretics.
Conversely, other diuretics can increase
hypokalemia risk. We assessed the effects of
the sodium glucose co-transporter 2 (SGLT2)
inhibitor dapagliflozin on serum potassium
levels in a pooled analysis of clinical trials in
patients with type 2 diabetes mellitus (T2DM).
Methods: Fourteen randomized, placebo
-controlled, double-blind T2DM studies were
analyzed: pooled data from 13 studies of
B24 weeks’ duration (dapagliflozin 10 mg,
N = 2360; placebo, N = 2295); and one
52-week moderate renal impairment study in
patients with baseline eGFR C30 to \60 mL/
min/1.73 m2 (dapagliflozin 10 mg, N = 85;
placebo, N = 84). Central laboratory serum
potassium levels were determined at each
study visit.
Results: No clinically relevant mean changes
from baseline in serum potassium B24 weeks
were reported for dapagliflozin 10 mg
[-0.05 mmol/L; 95% confidence interval (CI)
-0.07, -0.03] versus placebo (-0.02 mmol/L;
95% CI -0.04, 0.00) in the pooled population
or in the renal impairment study (-0.03mmol/L;
95% CI -0.14, 0.08 vs. -0.02 mmol/L; 95% CI
-0.13, 0.09, respectively). The incidence rate
ratio for serum potassium C5.5 mmol/L over
24 weeks for dapagliflozin 10 mg versus placebo
was 0.90 (95% CI 0.74, 1.10) in the pooled
population; with no increased risk in patients
receiving ARBs/ACE inhibitors, or
potassium-sparing diuretics, or in those with
moderate renal impairment. Slightly more
Electronic supplementary material The online
version of this article (doi:10.1007/s13300-015-0150-y)
contains supplementary material, which is available to
authorized users.
Y. Yavin (&)  A. Ptaszynska
Bristol-Myers Squibb, Princeton, NJ, USA
e-mail: yshai.yavin@bms.com
T. A. Mansfield
AstraZeneca, Fort Washington, PA, USA
K. Johnsson  E. Johnsson
AstraZeneca, Gothenburg, Sweden
S. Parikh
AstraZeneca, Gaithersburg, MD, USA
Diabetes Ther (2016) 7:125–137
DOI 10.1007/s13300-015-0150-y
patients receiving dapagliflozin 10 mg had
serum potassium B3.5 mmol/L versus placebo
(5.2% vs. 3.6%); however, no instances of serum
potassium B2.5 mmol/L were reported.
Conclusion: Dapagliflozin is not associated
with an increased risk of hyperkalemia or
severe hypokalemia in patients with T2DM.
Funding: Bristol-Myers Squibb and
AstraZeneca.
Keywords: Dapagliflozin; Hyperkalemia;
Hypokalemia; Potassium; Sodium glucose
co-transporter 2 inhibitor; Type 2 diabetes
mellitus
INTRODUCTION
Hyperkalemia, defined as a serum potassium
level of greater than 5.5 mmol/L [1], is a
potentially life-threatening condition that
causes increased cardiac depolarization and
can lead to rapid electrocardiographic changes
and an increased risk of arrhythmias [2].
Conversely, hypokalemia is defined as a serum
potassium level of less than 3.5 mmol/L (mild)
[3] or less than 2.5 mmol/L (severe) [4] and can
lead to an increase in the risk of cardiac
arrhythmias [3]. In addition to the risk
associated with serum potassium outside the
normal range (i.e., below or above normal
levels), maintaining stable serum potassium
values within physiological levels is important,
as high serum potassium fluctuations are
associated with increased all-cause and
cardiovascular mortality [5].
Patients with diabetes are at increased risk of
hyperkalemia [6, 7] and diabetes is an
independent risk factor for hyperkalemia [6, 8,
9]. In an outpatient population of patients with
diabetes, the prevalence of hyperkalemia has
been estimated at 4% [6], whereas in a separate
investigation in the general population, it has
been estimated to be lower (0.3%) [10].
Additionally, diabetes is associated with a high
incidence of renal impairment, which in turn is
an independent risk factor for hyperkalemia [9].
Antihypertensive medications, which are
frequently prescribed to these patients, can
also increase serum potassium [11, 12]. For
example, medications that reduce renal
potassium excretion by inhibiting the
renin-angiotensin-aldosterone system [such as
angiotensin-converting enzyme (ACE)
inhibitors and angiotensin receptor blockers
(ARBs)], and drugs that inhibit the epithelial
sodium channel (known as potassium-sparing
diuretics) are associated with a greater
hyperkalemia risk [13, 14]. The combination of
an ACE inhibitor or ARB and a
potassium-sparing diuretic is likely to further
increase potassium levels and has been shown
to precipitate life-threatening hyperkalemia in
patients with diabetes [15–17]. Conversely,
other diuretics such as thiazides or loop
diuretics are generally associated with an
increased risk of hypokalemia [18].
Older patients with diabetes have an
increased susceptibility to hyperkalemia due to
a number of factors, including an age-related
decline in renal function and pharmaceutical
side effects, such as those associated with ACE
inhibitor or ARB treatment [19].
Sodium glucose co-transporter 2 (SGLT2)
inhibitors are a class of glucose-lowering drugs
that improve glycemic control, produce
favorable effects on body weight and blood
pressure, and have a low associated risk of
hypoglycemia [20]. Given the renal site of
action of SGLT2 inhibitors and the mild
diuresis associated with their mode of action
[21], there is potential concern about their
effects on electrolyte balance, including
potassium. Indeed, the SGLT2 inhibitor
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canagliflozin is associated with an increased risk
of hyperkalemia [22].
Dapagliflozin is a highly selective orally
available SGLT2 inhibitor for the treatment of
type 2 diabetes mellitus (T2DM) [23]. Phase IIb
and III clinical studies have demonstrated that
dapagliflozin has a favorable safety profile and is
well tolerated as monotherapy [24] or in
combination with other glucose-lowering
agents [25–29]. Here we describe the results of
a pooled analysis of dapagliflozin clinical trials
in patients with T2DM that aimed to determine
whether or not dapagliflozin 10 mg affected the
risk of potassium imbalance.
METHODS
Patient Population
The analyzed population comprised short-term
pooled data from 13 placebo-controlled,
double-blind, Phase IIb and III studies of up
to 24 weeks’ duration, in which patients with
T2DM were treated with dapagliflozin 10 mg
(N = 2360) or placebo (N = 2295; Table S1 in
the supplementary material). The analysis
consisted of three Phase IIb studies with
durations of 12 weeks, and 10 Phase III
studies with durations of 24 weeks. All
patients had a baseline estimated glomerular
filtration rate (eGFR) of C30 mL/min/1.73 m2,
with the exception of 1 patient in each
treatment group.
Data from a Phase II/III 52-week dedicated
renal impairment study [30], in which all
patients had an eGFR at baseline of C30 to
\60 mL/min/1.73 m2, were analyzed separately
[dapagliflozin 10 mg (N = 85); placebo (N = 84)].
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
Outcomes Measures
Serum potassium levels were determined for
each patient by central laboratory
measurements at every study visit (at baseline,
week 1 and week 4, then every 4 weeks up to
week 24). Mean change in serum potassium
levels from baseline were determined for
dapagliflozin 10 mg versus placebo. This
outcome was assessed in the pooled
population (overall and in patients treated
with ACE inhibitors or ARBs) up to week 24,
and in the moderate renal impairment study
over 52 weeks [30].
The incidence of marked abnormalities of
serum potassium C5.5 mmol/L and C6.0 mmol/
L were determined for dapagliflozin 10 mg
compared with placebo. These cut-off points
were selected as hyperkalemia is generally
defined as a serum potassium level at or above
the upper limit of normal (C5.5 mmol/L) [1],
whereas moderate hyperkalemia is generally
defined as a serum potassium level of
C6.0–6.9 mmol/L [31].
Marked abnormalities of serum potassium
reported as adverse events (AEs) or serious AEs
(SAE; defined as those events meeting the
International Conference on Harmonisation/
Good Clinical Practice criteria for an SAE [32])
were assessed for dapagliflozin 10 mg versus
placebo for the overall pooled population. The
incidence of mild and severe hypokalemia
(serum potassium B3.5 and B2.5 mmol/L,
respectively) was also determined for
dapagliflozin 10 mg versus placebo for the
overall pooled population.
Analysis Methods
Presented mean changes from baseline and
associated 95% confidence intervals (CI),
which were calculated using the t-distribution
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method, were conducted with SAS/STAT (SAS
Institute Inc. Cary, NC, USA). For the analysis
of the incidence of marked abnormalities of
serum potassium, incidence rate ratios (IRR)
and associated 95% CIs, which were stratified
by study, were calculated post hoc using exact
methods with StatXact (Cytel, Cambridge,
MA, USA). The IRR was defined as the rate of
the event in the dapagliflozin group divided
by the rate in the placebo group. Thus, an IRR
upper 95% CI of \1 (1 being the null value)
would indicate that dapagliflozin was
associated with a lower incidence of marked
abnormalities of serum potassium than
placebo. Conversely, an IRR lower 95% CI of
[1 would indicate that dapagliflozin was
associated with a higher incidence of marked
abnormalities of serum potassium than
placebo. No statistical hypothesis testing was
conducted and no p values were calculated. All
analyses were performed using all available
data regardless of the use of rescue therapy.
Mean eGFR was determined using the




Mean baseline demographic characteristics were
well balanced between the dapagliflozin and
placebo groups in the pooled population
(Table 1). A high proportion of patients
received an ACE inhibitor or ARB (65.9% in
the dapagliflozin group and 68.2% in the
placebo group) whereas only a small
proportion of patients were treated with a
potassium-sparing diuretic (5.0% with
dapagliflozin vs. 5.6% with placebo). The
majority of patients treated with a
potassium-sparing diuretic also received an
ACE inhibitor or ARB (82.4% with
dapagliflozin and 80.5% with placebo).
Patients in the dedicated moderate renal
impairment study [30] were older than the
pooled population (mean age: dapagliflozin
10 mg, 68 years and placebo, 67 years; vs. 58.4
and 58.9 years in the pooled population,
respectively) and had a longer duration of
T2DM (mean duration: dapagliflozin 10 mg,
18.2 years and placebo, 15.7; vs. 8.9 and
8.8 years in the pooled population,
respectively; Table 1).
Mean Change in Potassium from Baseline
up to Week 24
No clinically relevant mean change from
baseline in serum potassium was noted up to
24 weeks in the pooled population:
-0.05 mmol/L (95% CI -0.07, -0.03) in the
dapagliflozin 10 mg group compared with
-0.02 mmol/L (95% CI -0.04, 0.00) in the
placebo group (Fig. 1). Similarly, no clinically
relevant mean changes from baseline in serum
potassium over 24 weeks were noted with
dapagliflozin versus placebo in the pooled
population of patients treated with ACE
inhibitors or ARBs [-0.04 mmol/L (95% CI
-0.07, -0.02) vs. -0.01 mmol/L (95% CI
-0.03, 0.01), respectively, at week 24; Fig. 2a]
or potassium-sparing diuretics [-0.06 mmol/L
(95% CI -0.15, 0.02), vs. 0.00 mmol/L (95% CI:
-0.09, 0.09), respectively, at week 24; Fig. 2b].
There were no clinically relevant mean changes
from baseline in serum potassium in patients
with moderate renal impairment [30] at
24 weeks [-0.03 mmol/L (95% CI -0.14, 0.08)
vs. -0.02 mmol/L (95% CI -0.13, 0.09) for
dapagliflozin 10 mg and placebo groups,
respectively] or week 52 [-0.09 mmol/L
(95% CI -0.19, 0.01) vs. 0.00 mmol/L (95% CI
-0.11, 0.11), respectively; Fig. 2c].
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Table 1 Baseline demographic and disease characteristics









Mean age, years (SD) 58.4 (10.02) 58.9 (9.96) 68 (7.7) 67 (8.6)
Age, n (%)
\65 years 1695 (71.8) 1584 (69.0) 29 (34.1) 36 (42.9)
C65 years 665 (28.2) 711 (31.0) 56 (65.9) 48 (57.1)
C75 years 98 (4.2) 81 (3.5) 16 (18.8) 19 (22.6)
Female, n (%) 1003 (42.5) 952 (41.5) 29 (34.1) 31 (36.9)
Race, n (%)
White 1976 (83.7) 1930 (84.1) 77 (90.6) 69 (82.1)
Black 81 (3.4) 73 (3.2) 4 (4.7) 1 (1.2)
Asian 209 (8.9) 206 (9.0) 3 (3.5) 6 (7.1)
Other 94 (4.0) 86 (3.7) 1 (1.2) 8 (9.5)
Region, n (%)
North America 769 (32.6) 705 (30.7) 48 (56.5) 41 (48.8)
Latin America 423 (17.9) 407 (17.7) 17 (20.0) 23 (27.4)
Europe 952 (40.3) 976 (42.5) 9 (10.6) 11 (13.1)
Asia/Paciﬁc 216 (9.2) 207 (9.0) 11 (12.9) 9 (10.7)
Mean HbA1c, % (SD) 8.18 (0.94) 8.17 (0.94) 8.22 (0.98) 8.53 (1.28)
Mean FPG, mg/dL (SD) 164.8 (46.6) 165.4 (45.3) 164 (66) 149 (48)
BMI, n (%)
C25 kg/m2 2187 (92.7) 2086 (90.9) 80 (94.1) 75 (89.3)
C30 kg/m2 1478 (62.6) 1410 (61.4) 54 (63.5) 50 (59.5)
T2DM duration, years (SD) 8.9 (8.0) 8.8 (8.0) 18.2 (10.1) 15.7 (9.5)
Mean systolic BP, mmHg (SD) 131.7 (15.3) 131.6 (14.9) 133.7 (17.0) 130.7 (14.1)
Systolic BP C130 mmHg, n (%) 1273 (53.9) 1227 (53.5) 52 (61.2) 46 (54.8)
eGFR C30 to\60 L/min/
1.73 m2, n (%)
265 (11.2) 268 (11.7) 80 (94.1) 75 (89.3)
Antihypertensive medication, n (%)
ACE inhibitor or ARB 1555 (65.9) 1566 (68.2) 71 (83.5) 73 (86.9)
Potassium-sparing diuretic 119 (5.0) 128 (5.6) 6 (7.1) 6 (7.1)
Loop diuretics 202 (8.6) 209 (9.1) 26 (30.6) 26 (31.0)
Thiazide diuretics 443 (18.8) 434 (18.9) 34 (40.0) 27 (32.1)
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, BMI body mass index, BP blood pressure, eGFR
estimated glomerular ﬁltration rate, FPG fasting plasma glucose, HbA1c glycated hemoglobin, SD standard deviation,
T2DM type 2 diabetes mellitus
a Pooled data from 13 studies of up to 24 weeks in duration
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Incidence of Marked Abnormalities
of Serum Potassium ‡5.5 and ‡6.0 mmol/L
The incidence of serum potassium reported at or
above the upper limit of normal (5.5 mmol/L) up
to 24 weeks was similar for dapagliflozin 10 mg
and placebo overall in the pooled population of
patients [8.6% vs. 9.5%, respectively; IRR 0.90
(95% CI 0.74, 1.10)], and for subgroups of
patients in the pooled population on ACE
inhibitors or ARBs, or with low eGFR (Fig. 3).
The IRR upper 95% CI for serum potassium
C5.5 mmol/L up to 24 weeks was below 1 for
dapagliflozin 10 mg versus placebo for patients
on potassium-sparing diuretics and for patients
with an eGFR of C30 to \60 mL/min/1.73 m2
on ACE inhibitors or ARBs (Fig. 3). In the
52 week moderate renal impairment study
[30], the incidence of serum potassium
C5.5 mmol/L was 20.2% with dapagliflozin
10 mg and 26.5% with placebo [IRR 0.69
(95% CI 0.34, 1.35); Fig. 3], with fewer patients
treated with dapagliflozin discontinuing due to
hyperkalemia (4.7% vs. 9.5%, respectively).
Likewise, when the higher serum potassium
cut-off point of C6.0 mmol/L was used, the
Fig. 1 Mean change from baseline in serum potassium up
to 24 weeks for pooled population. Asterisks number of
patients for each visit is the number of treated patients
with non-missing values at baseline and at that study visit.
Data points are shifted horizontally to prevent overlap of
CI bars. BL baseline, CI conﬁdence interval, DAPA
dapagliﬂozin, SD standard deviation
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incidence of marked abnormalities with
dapagliflozin 10 mg was similar to placebo for
patients overall (3.0% vs. 2.7%, respectively),
with an IRR of 1.08 (95% CI 0.76, 1.55). For all
subgroups, IRR analysis of marked abnormalities
of serum potassium C6.0 mmol/L had 95% CIs
that included the null value of 1, suggesting that
there were no differences between the
dapagliflozin 10 mg and placebo groups [IRR
(95% CI) by patient subgroup: ACE inhibitor/
ARB, 1.16 (0.78, 1.74); ACE inhibitor/ARB or
potassium-sparing diuretic, 1.16 (0.78, 1.75);
eGFR C30 to\60 mL/min/1.73 m2, 0.60 (0.23,
1.51); eGFRC30 to\60 mL/min/1.73 m2 on ACE
inhibitor/ARB, 0.54 (0.19, 1.40)]. Furthermore,
there was no meaningful difference between
dapagliflozin 10 mg and placebo in the
incidence of marked abnormalities of serum
potassium of C6.0 mmol/L in the moderate
renal impairment study [30] (IRR 0.34 [95% CI
0.06, 1.41]).
Distribution of Marked Abnormalities
of Serum Potassium ‡5.5 mmol/L
Marked abnormalities of serum potassium for
patients in the dapagliflozin 10 mg and placebo
groups were most commonly limited to the
5.50–5.75 mmol/L range [91 (45.3%) vs. 113
(52.6%), respectively; Fig. 4].
Marked Abnormalities of Serum Potassium
‡5.5 mmol/L Reported as Adverse Events
Very few marked abnormalities of increased
potassium were reported by the individual
study investigators as clinical AEs: 7 (0.3%) in
the dapagliflozin 10 mg group versus 0 in the
placebo group. One SAE of hyperkalemia (serum
potassium of 6.4 mmol/L on day 169 of
treatment) was reported in the dapagliflozin
bFig. 2 Mean change from baseline in serum potassium levels
in patients at increased risk of hyperkalemia. Patients receiving
a ACE inhibitors or ARBs and b potassium-sparing diuretics
in the pooled population (study duration B24 weeks);
c patients with moderate renal impairment [30] (study
duration 52 weeks). Asterisks number of treated patients with
non-missing values at baseline and at that study week. ACE
angiotensin-converting enzyme, ARBs angiotensin receptor
blockers, BL baseline, CI conﬁdence interval, DAPA
dapagliﬂozin, SD standard deviation
Fig. 3 Incidence rate ratio of marked abnormalities of
serum potassium C5.5 mmol/L. Asterisks short-term pooled
data up to 24 weeks; dagger moderate renal impairment
study (52 weeks) [30]. ACEi angiotensin-converting
enzyme inhibitors, ARBs angiotensin receptor blockers, CI
conﬁdence interval, DAPA dapagliﬂozin, eGFR estimated
glomerular ﬁltration rate, IRR incidence rate ratio
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10 mg group. This patient had a history of
hyperkalemia and hypertension and was treated
with perindopril, which was stopped on
day 175. His re-test potassium measurement
was 6.1 mmol/L on day 176 and on day 178
this had decreased further to 4.5 mmol/L, at
which point the SAE was considered resolved.
Dapagliflozin dosing was not interrupted during
this time.
All other AEs of hyperkalemia reported for
patients in the dapagliflozin 10 mg group were
reported as mild or moderate and had resolved
by the next laboratory measurement (7 to
25 days later). No other patients had an AE
that required treatment and no patients
discontinued due to an AE of hyperkalemia.
Marked Abnormalities of Serum Potassium
£2.5 and £3.5 mmol/L
The proportion of patients with a serum
potassium level of B3.5 mmol/L was slightly
higher with dapagliflozin 10 mg than placebo in
the overall pooled population [5.2% vs. 3.6%,
respectively; IRR 1.40 (95% CI 1.05, 1.87);
Fig. 5], and for subgroups of patients in the
pooled population receiving thiazide diuretics
[7.9% vs. 6.7%; IRR 1.24 (95% CI 0.73, 2.11)] or
loop diuretics [7.4% vs. 5.3%; IRR 1.56 (95% CI
0.65, 3.93)].
Few marked abnormalities of potassium
B3.5 mmol/L were reported as AEs [9 (0.4%)
vs. 4 (0.2%) with dapagliflozin 10 mg vs.
placebo, respectively]. None of these AEs
resulted in discontinuation and the majority
were mild in intensity [8 (0.3%) with
dapagliflozin 10 mg vs. 2 (0.1%) with
placebo], with no severe events reported. In
total, 6 (0.3%) patients in the dapagliflozin
group and 1 (\0.1%) patient in the placebo
group had an AE of hypokalemia that required
intervention.
There were no reports of a serum potassium
level of B2.5 mmol/L in the pooled population.
Fig. 4 Distribution of marked abnormalities of serum potassium C5.5 mmol/L for short-term pooled data up to 24 weeks
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DISCUSSION
The effect of dapagliflozin on serum potassium
levels in over 4000 patients with T2DM across
the dapagliflozin clinical trials program, and
for a duration of up to 24 weeks was explored.
No clinically relevant mean changes from
baseline in serum potassium were noted in
patients receiving dapagliflozin 10 mg or
placebo, and few marked abnormalities of
serum potassium were reported in either
group; all cases resolved without treatment
and did not lead to discontinuation.
Furthermore, no clinically relevant changes
from baseline in serum potassium and no
differences in marked abnormalities in serum
potassium were reported with dapagliflozin
10 mg compared with placebo in patients at
higher risk of hyperkalemia, such as those with
moderate renal impairment or those receiving
treatment with ACE inhibitors, ARBs or
potassium-sparing diuretics. While this
analysis indicated that dapagliflozin did not
increase hyperkalemia risk in patients with
moderate renal impairment, dapagliflozin is
not indicated for use in patients with moderate
or low renal function (eGFR \60 mL/min/
1.73 m2) [34]. The frequency of any
hyperkalemia episode (i.e., serum potassium
level C5.5 mmol/L) in the overall pooled
population was approximately 9% for both
the dapagliflozin 10 mg and placebo groups,
whereas moderate or severe episodes of
hyperkalemia (i.e., patients with a serum
potassium level C6.0 mmol/L) occurred in 3%
of patients in both groups. The majority of
these episodes were asymptomatic and few AEs
of potassium C5.5 mmol/L were reported (0.3%
vs. 0.0% with dapagliflozin and placebo,
respectively).
Episodes of mild hypokalemia (serum
potassium B3.5 mmol/L) in the pooled
population were slightly more frequent with
dapagliflozin than with placebo. As expected,
these episodes were more common in patients
receiving loop diuretics or thiazide diuretics
both in patients taking dapagliflozin and
placebo, with no relevant difference between
the groups. Few AEs of hypokalemia were
reported in either group (0.4% with
dapagliflozin vs. 0.2% with placebo), and did
not lead to discontinuation. There were no
Fig. 5 Incidence rate ratio of marked abnormalities of serum potassium B3.5 mmol/L. Asterisks short-term pooled data up
to 24 weeks. CI conﬁdence interval, DAPA dapagliﬂozin, IRR incidence rate ratio
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reports of severe hypokalemia (serum potassium
B2.5 mmol/L) in the pooled population.
A trend towards increased hypokalemia risk
could be consistent with dapagliflozin’s mild
diuretic effect [35]; however, a lack of any
difference between the groups when used with
typical diuretics is both reassuring and
somewhat unexpected. Renal potassium
excretion is a complex process that is
primarily determined by the serum
aldosterone concentration and driven by the
sodium concentration in the distal nephron
[31, 36]. Due to the co-transportation of sodium
and glucose, transient increases in urinary
sodium excretion are seen for a few days upon
initiation of dapagliflozin, after which levels
tend to normalize [23]. Thus, unlike typical
diuretics, long-term treatment with
dapagliflozin should not affect sodium delivery
to the distal nephron. However, it should be
acknowledged that in a previous small
exploratory study [35], dapagliflozin treatment
increased median plasma renin activity relative
to placebo, to approximately a quarter of the
hydrochlorothiazide 25 mg effect, and
increased median serum aldosterone activity
to a similar extent as hydrochlorothiazide. A
potential trend for hypokalemia does not seem
to be explained by dapagliflozin’s mechanism of
action, which is not reported to promote
kaliuresis [34], neither is it consistent across
the SGLT2 inhibitor class, as the SGLT2
inhibitor canagliflozin has been associated
with an increased risk of hyperkalemia.
Hyperkalemia risk with canagliflozin was
greater in patients with moderate renal
impairment or receiving ACE inhibitors, ARBs
or potassium-sparing diuretics [22], and was
more pronounced with the canagliflozin
300 mg dose than the 100 mg dose [37].
Hyperkalemia risk is greater in patients with
diabetes, which may be partly attributed to
hyperosmolarity caused by hyperglycemia,
resulting in a shift in potassium out of cells
[38]. Impaired elimination of potassium can
also increase the risk of hyperkalemia [31, 36],
particularly in patients with reduced renal
function or those treated with ACE inhibitors,
ARBs or potassium-sparing diuretics [36].
Monitoring potassium levels is an important
consideration in patients with diabetes,
particularly as these patients often have
hypertension and may be treated with ACE
inhibitors, ARBs and/or potassium-sparing
diuretics, making them more susceptible to
hyperkalemia [13, 14]. Likewise, potassium
monitoring may be important in patients with
renal impairment [12], who are also considered
to be at high risk of hyperkalemia [9]. Clinicians
should balance the opposing risks of avoiding
hyperkalemia and causing hypokalemia, or vice
versa. For example, potassium-sparing diuretics
have been shown to prevent diuretic-induced
hypokalemia but are associated with an
increased risk of hyperkalemia [39].
Furthermore, combinations of drugs with an
associated risk of hyperkalemia (e.g., ACE
inhibitor, ARBs, potassium-sparing diuretics
[15–17]) or hypokalemia (e.g., thiazides or
loop diuretics [18]) may rapidly precipitate
serious serum electrolyte abnormalities.
Therefore, knowledge of the presence or
absence of an effect on potassium homeostasis
with antidiabetic drugs is important. Previous
studies indicate that dapagliflozin does not
affect potassium levels when taken in
combination with ACE inhibitors, ARBs,
thiazides or loop diuretics [40–42].
A limitation of this analysis was the low
number of patients in some of the subgroups
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(i.e., patients on potassium-sparing diuretics or
with low eGFR), restricting the reliability of the
assessment of risk for the AEs or marked
abnormalities in these patients.
CONCLUSIONS
Dapagliflozin does not appear to increase serum
potassium levels in patients with T2DM,
including patients at a higher risk of
hyperkalemia, such as those with moderate
renal impairment or treated with ACE
inhibitors, ARBs or potassium-sparing
diuretics. Furthermore, although there were
more episodes of hypokalemia overall in the
dapagliflozin group, dapagliflozin was not
associated with an increased risk of
hypokalemia in any of the patient categories
associated with increased hypokalemia risk.
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